Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study
Dan Mo,1 Songfang Liu,1 Hong Ma,1 Haoming Tian,1 Honglin Yu,2 Xiangxun Zhang,2 Nanwei Tong,2 Jiayu Liao,3,4 Yan Ren11Division of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, People’s Republic of China; 2Laboratory of Endocrinology and Metabolism,...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-08-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/effects-of-acarbose-and-metformin-on-the-inflammatory-state-in-newly-d-peer-reviewed-article-DDDT |
id |
doaj-66bc5c488f024351ad3d50952b6d1f30 |
---|---|
record_format |
Article |
spelling |
doaj-66bc5c488f024351ad3d50952b6d1f302020-11-24T21:59:55ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-08-01Volume 132769277647756Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical studyMo DLiu SMa HTian HYu HZhang XTong NLiao JRen YDan Mo,1 Songfang Liu,1 Hong Ma,1 Haoming Tian,1 Honglin Yu,2 Xiangxun Zhang,2 Nanwei Tong,2 Jiayu Liao,3,4 Yan Ren11Division of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, People’s Republic of China; 2Laboratory of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, People’s Republic of China; 3Department of Bioengineering, Bourns College of Engineering, University of California, Riverside, CA 92521, USA; 4West China Hospital-California Multiomics Research Center, Key Laboratory of Transplant Engineering and Immunology, National Health Commission of PRC, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaObjective: This study aimed to investigate the changes in inflammatory biomarkers between newly diagnosed type 2 diabetes (T2DM) patients under one-year acarbose treatments and those under metformin managements.Methods: Seventy patients with newly diagnosed T2DM and 32 volunteers with normal glucose tolerance (normal controls, NCs) were enrolled. Seventy patients with T2DM were randomly assigned to two subgroups and treated with acarbose (n=34) or metformin (n=36) for 1 year. Blood glucose, insulin, glycosylated hemoglobin (A1C), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and inflammatory biomarker levels (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-2 (IL-2), and ferritin) were detected at 0, 6 and 12 months.Results: After adjusting for sex, the waist-to-hip ratio (WHR) and body mass index (BMI), higher fasting plasma glucose (FPG), standard meal test 1/2 hr and 2 hr glucose, TG, TC, LDL-C, IL-6, TNF-α, IL-2 and ferritin levels were observed in T2DM group than in NCs (P<0.05). After 6 months of treatment, TNF-α levels were significantly decreased in both subgroups, and IL-6 and ferritin levels were significantly decreased after 12 months (P<0.05). However, no significant differences in the IL-6, TNF-α and ferritin levels were observed between the two subgroups. Moreover, significantly higher IL-6 and TNF-α levels were detected in the T2DM group than in NCs after 12 months of treatment (P<0.05).Conclusion: Patients with newly diagnosed T2DM exhibited a marked chronic inflammatory state characterized by increased IL-6, TNF-α, IL-1β, IL-2 and ferritin levels. After 1 year of treatment with acarbose or metformin, IL-6, TNF-α, IL-1β and ferritin levels were significantly decreased compared with the baseline. The anti-inflammatory effects of acarbose and metformin were comparable and required a long-term treatment (1 year), but the characteristics were different. Further investigations are needed to determine whether this effect was independent of the hypoglycemic effects.Keywords: newly diagnosed type 2 diabetes, inflammatory biomarkers, acarbose, metforminhttps://www.dovepress.com/effects-of-acarbose-and-metformin-on-the-inflammatory-state-in-newly-d-peer-reviewed-article-DDDTnewly diagnosed type 2 diabetesinflammatory biomarkersacarbosemetformin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mo D Liu S Ma H Tian H Yu H Zhang X Tong N Liao J Ren Y |
spellingShingle |
Mo D Liu S Ma H Tian H Yu H Zhang X Tong N Liao J Ren Y Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study Drug Design, Development and Therapy newly diagnosed type 2 diabetes inflammatory biomarkers acarbose metformin |
author_facet |
Mo D Liu S Ma H Tian H Yu H Zhang X Tong N Liao J Ren Y |
author_sort |
Mo D |
title |
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study |
title_short |
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study |
title_full |
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study |
title_fullStr |
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study |
title_full_unstemmed |
Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study |
title_sort |
effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2019-08-01 |
description |
Dan Mo,1 Songfang Liu,1 Hong Ma,1 Haoming Tian,1 Honglin Yu,2 Xiangxun Zhang,2 Nanwei Tong,2 Jiayu Liao,3,4 Yan Ren11Division of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, People’s Republic of China; 2Laboratory of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, People’s Republic of China; 3Department of Bioengineering, Bourns College of Engineering, University of California, Riverside, CA 92521, USA; 4West China Hospital-California Multiomics Research Center, Key Laboratory of Transplant Engineering and Immunology, National Health Commission of PRC, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaObjective: This study aimed to investigate the changes in inflammatory biomarkers between newly diagnosed type 2 diabetes (T2DM) patients under one-year acarbose treatments and those under metformin managements.Methods: Seventy patients with newly diagnosed T2DM and 32 volunteers with normal glucose tolerance (normal controls, NCs) were enrolled. Seventy patients with T2DM were randomly assigned to two subgroups and treated with acarbose (n=34) or metformin (n=36) for 1 year. Blood glucose, insulin, glycosylated hemoglobin (A1C), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and inflammatory biomarker levels (interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-2 (IL-2), and ferritin) were detected at 0, 6 and 12 months.Results: After adjusting for sex, the waist-to-hip ratio (WHR) and body mass index (BMI), higher fasting plasma glucose (FPG), standard meal test 1/2 hr and 2 hr glucose, TG, TC, LDL-C, IL-6, TNF-α, IL-2 and ferritin levels were observed in T2DM group than in NCs (P<0.05). After 6 months of treatment, TNF-α levels were significantly decreased in both subgroups, and IL-6 and ferritin levels were significantly decreased after 12 months (P<0.05). However, no significant differences in the IL-6, TNF-α and ferritin levels were observed between the two subgroups. Moreover, significantly higher IL-6 and TNF-α levels were detected in the T2DM group than in NCs after 12 months of treatment (P<0.05).Conclusion: Patients with newly diagnosed T2DM exhibited a marked chronic inflammatory state characterized by increased IL-6, TNF-α, IL-1β, IL-2 and ferritin levels. After 1 year of treatment with acarbose or metformin, IL-6, TNF-α, IL-1β and ferritin levels were significantly decreased compared with the baseline. The anti-inflammatory effects of acarbose and metformin were comparable and required a long-term treatment (1 year), but the characteristics were different. Further investigations are needed to determine whether this effect was independent of the hypoglycemic effects.Keywords: newly diagnosed type 2 diabetes, inflammatory biomarkers, acarbose, metformin |
topic |
newly diagnosed type 2 diabetes inflammatory biomarkers acarbose metformin |
url |
https://www.dovepress.com/effects-of-acarbose-and-metformin-on-the-inflammatory-state-in-newly-d-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT mod effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT lius effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT mah effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT tianh effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT yuh effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT zhangx effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT tongn effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT liaoj effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy AT reny effectsofacarboseandmetforminontheinflammatorystateinnewlydiagnosedtype2diabetespatientsaoneyearrandomizedclinicalstudy |
_version_ |
1725846525160980480 |